All Phenotypes Trp53<tm3.1Glo> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Trp53^tm3.1Glo
targeted mutation 3.1, Guillermina Lozano
MGI:3528279

Summary

14 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Trp53^tm3.1Glo/Trp53^tm3.1Glo	B6.129S7-Trp53^tm3.1Glo	MGI:3722620
ht2	Trp53^tm3.1Glo/Trp53⁺	B6.129S7-Trp53^tm3.1Glo	MGI:3576493
ht3	Trp53^tm1Tyj/Trp53^tm3.1Glo	involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6	MGI:3722619
ht4	Trp53^tm3.1Glo/Trp53^tm4Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:5000508
cn5	Trp53^tm3.1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc/0	involves: 129S7/SvEvBrd * C57BL/6 * CBA	MGI:5000509
cx6	Pml^tm1Ppp/Pml⁺ Trp53^tm3.1Glo/Trp53^tm3.1Glo	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485800
cx7	Pml^tm1Ppp/Pml^tm1Ppp Trp53^tm3.1Glo/Trp53⁺	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485838
cx8	Pml^tm1Ppp/Pml⁺ Trp53^tm3.1Glo/Trp53⁺	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485831
cx9	Pml^tm1Ppp/Pml^tm1Ppp Trp53^tm3.1Glo/Trp53^tm3.1Glo	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485803
cx10	Mdm2^tm3.1Glo/Mdm2^tm3.1Glo Trp53^tm3.1Glo/Trp53⁺	B6.129S-Mdm2^tm3.1Glo Trp53^tm3.1Glo	MGI:4835498
cx11	Mdm2^tm4.1Glo/Mdm2^tm4.1Glo Trp53^tm3.1Glo/Trp53⁺	B6.129S-Mdm2^tm4.1Glo Trp53^tm3.1Glo	MGI:4835500
cx12	Mdm4^tm3.1Glo/Mdm4^tm3.1Glo Trp53^tm3.1Glo/Trp53^tm3.1Glo	involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N	MGI:5142303
cx13	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm3.1Glo/Trp53^tm4Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:5000504
cx14	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm3.1Glo/Trp53⁺	involves: 129S7/SvEvBrd * C57BL/6	MGI:3576494

Allelic Composition	Trp53^tm3.1Glo/Trp53^tm3.1Glo
Genetic Background	B6.129S7-Trp53^tm3.1Glo

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:95318 , J:317504 )

	• homozygous mutants die between 50 to 250 days after birth, however this survival curve is no different from homozygous null Trp53 mice (J:95318)
	• mean survival of male mice is 164.5 days (J:317504)

prenatal lethality, incomplete penetrance ( J:317504 )

• only 11% of females are born, indicating a severe reduction in female survival

neoplasm

increased lymphoma incidence ( J:95318 )

• 70% of mice develop lymphomas

increased sarcoma incidence ( J:95318 )

• 29% of mice develop sarcomas

homeostasis/metabolism

increased DNA replication ( J:95318 )

• DNA synthesis rates for mouse fibroblast cells continue to synthesize DNA after 10 days in culture whereas MEFs from a Trp53^tm1Tyj homozygote are quiescent at day 6

cellular

increased fibroblast proliferation ( J:95318 )

• at day 4 of culture, mouse embryonic fibroblast (MEF)cells reach a higher saturation concentration than do MEFs from a Trp53^tm1Tyj homozygote

increased DNA replication ( J:95318 )

• DNA synthesis rates for mouse fibroblast cells continue to synthesize DNA after 10 days in culture whereas MEFs from a Trp53^tm1Tyj homozygote are quiescent at day 6

Allelic Composition	Trp53^tm3.1Glo/Trp53⁺
Genetic Background	B6.129S7-Trp53^tm3.1Glo

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:95318 , J:317504 )

• heterozygous mutants die between 150 to 750 days after birth, however this survival curve is no different from heterozygous Trp53 mice (J:95318)

• median survival for the combined population of both males and females is 499 days i.e., similar to that of mice heterozygous for both Trp53^tm3.1Glo and Pml^tm1Ppp (504 days) (J:317504)

• median survival is 515 days for male mice and 463 days for female mice (J:317504)

neoplasm

increased metastatic potential ( J:95318 )

• the osteosarcomas and carcinomas of heterozygous mutants metastasized when compared to heterozygous Trp53^tm1Tyj mice

increased lymphoma incidence ( J:95318 , J:317504 )

• 31.5% of heterozygous mutants developed lymphomas (J:95318)

• 52% of mice develop lymphomas (when expressed as a % of tumor type); 13% of mice develop two tumor types, lymphomas and sarcomas (J:317504)

• 44% of mice exhibit lymphomas when tumor incidence is evaluated per mouse, including those that succumb to EMH, and expressed as a % disease/total number of mice (J:317504)

• when tumors are segregated by gender, 50% of males and 38% of females exhibit lymphomas (expressed as a % disease/total number of mice) (J:317504)

increased T cell derived lymphoma incidence ( J:317504 )

• only ~10% of lymphoid tumors are T-cell lymphomas

increased B cell derived lymphoma incidence ( J:317504 )

• immunophenotyping of lymphocytes from terminally resected tumors showed that ~90% of lymphoid tumors are B-cell lymphomas

increased carcinoma incidence ( J:95318 , J:317504 , J:317504 )

	• 15.5% of heterozygous mutants developed carcinomas, which are rare in homozygotes (J:95318) • 4% of mice develop carcinomas (whether expressed as a % of tumor type or as a % disease/total number of mice) (J:317504)
	• when tumors are segregated by gender, 0% of males and 8% of females exhibit carcinomas (expressed as a % disease/total number of mice) (J:317504)

increased sarcoma incidence ( J:95318 , J:317504 )

• 53% of heterozygous mutants developed sarcomas (J:95318)

• 43% of mice develop sarcomas (when expressed as a % of tumor type); 13% of mice develop two tumor types, lymphomas and sarcomas (J:317504)

• 37% of mice exhibit sarcomas (when expressed as a % disease/total number of mice) (J:317504)

• when tumors are segregated by gender, 14% of males and 8% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice) (J:317504)

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 14% of males and 38% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

cellular

abnormal cell cycle ( J:95318 )

• higher DNA synthesis in MEFs with cells continuing to synthesize DNA between days 6 and 10 of culture compared to wildtype or heterozygous or homozygous Trp53^tm1Tyj MEFs which reached a quiescent state at day 6 and did not reenter the cell cycle

decreased cellular sensitivity to gamma-irradiation ( J:95318 )

• irradiated E13.5 heterozygous embryos showed no evidence of apoptosis in the hypothalamus compared to wildtype and heterozygous Trp53^tm1Tyj mutants that showed a high number of apoptotic cells

increased fibroblast proliferation ( J:95318 )

• MEFs initially did not show any significant differences in growth rate but by day 4, grew more rapidly than wildtype or heterozygous or homozygous null Trp53^tm1Tyj MEFs and reached a much higher saturation density

hematopoietic system

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

extramedullary hematopoiesis ( J:317504 )

• 41% mice exhibit extramedullary hematopoiesis (EMH), with no histological evidence of transformation to acute leukemia

• EMH is associated with peripheral blood leukocytosis and macrocytic anemia, indicative of a myeloproliferative/myelodysplastic overlap

• when segregated by gender, 43% of males and 31% of females exhibit EMH

macrocytic anemia ( J:317504 )

• mice with EMH exhibit macrocytic anemia

increased leukocyte cell number ( J:317504 )

• mice with EMH exhibit peripheral blood leukocytosis

immune system

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

increased leukocyte cell number ( J:317504 )

• mice with EMH exhibit peripheral blood leukocytosis

liver/biliary system

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

growth/size/body

decreased body weight ( J:317504 )

• average body weight is significantly lower than that in C57BL/6 wild-type controls

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

skeleton

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 14% of males and 38% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:317504 )

• only ~10% of lymphoid tumors are T-cell lymphomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Li-Fraumeni syndrome		DOID:3012	OMIM:PS151623	J:95318

Allelic Composition	Trp53^tm1Tyj/Trp53^tm3.1Glo
Genetic Background	involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53^tm1Tyj mutation (12 available); any Trp53 mutation (232 available)
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:95318 )

• mice do not survive past 300 days compared to Trp53^tm1Tyj heterozygotes and Trp53^tm3.1Glo heterozygotes that live to 900 days

Allelic Composition	Trp53^tm3.1Glo/Trp53^tm4Glo
Genetic Background	involves: 129S7/SvEvBrd * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)
Trp53^tm4Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

decreased tumor-free survival time ( J:171821 )

• median survival is 160 days due to tumor development

neoplasm

abnormal tumor morphology ( J:171821 )

• tumors exhibit interstitial inflammatory cells unlike in tumors from Trp53^tm3.1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

increased lymphoma incidence ( J:171821 )

• in 60% of mice (including T cell, diffuse, and large cell)

increased adenocarcinoma incidence ( J:171821 )

• in 4% of mice

increased spindle cell carcinoma incidence ( J:171821 )

increased sarcoma incidence ( J:171821 )

• in 37% of mice (including angiosarcoma, spindle-cell, and giant-cell)

Allelic Composition	Trp53^tm3.1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc/0
Genetic Background	involves: 129S7/SvEvBrd * C57BL/6 * CBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CAG-cre/Esr1*)5Amc mutation (9 available)
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)
Trp53^tm4Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

extended life span ( J:171821 )

• tamoxifen-treated mice survive longer than Trp53^tm3.1Glo/Trp53^tm4Glo mice

neoplasm

abnormal tumor pathology ( J:171821 )

• tamoxifen-treated lymphomas exhibit increased apoptosis response compared with tumors from Trp53^tm1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

• 3 of 5 tamoxifen-treated lymphomas exhibit senescence unlike in tumors from Trp53^tm1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

• tamoxifen-treated angiosarcomas and lymphomas exhibit senescence

decreased tumor growth/size ( J:171821 )

• tamoxifen-treated mice exhibit little to no tumor growth unlike in control mice

Allelic Composition	Pml^tm1Ppp/Pml⁺ Trp53^tm3.1Glo/Trp53^tm3.1Glo
Genetic Background	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pml^tm1Ppp mutation (2 available); any Pml mutation (91 available)
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:317504 )

• mean survival of male mice is 150 days, i.e., not significantly different from that in males homozygous for Trp53^tm3.1Glo alone (164.5 days)

prenatal lethality, incomplete penetrance ( J:317504 )

• only 12% of females are born, indicating a severe reduction in female survival

Allelic Composition	Pml^tm1Ppp/Pml^tm1Ppp Trp53^tm3.1Glo/Trp53⁺
Genetic Background	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

decreased tumor-free survival time ( J:317504 , J:317504 )

• median survival for the combined population of both males and females is 448 days, i.e., ~50 days shorter than in mice heterozygous for Trp53^tm3.1Glo alone (499 days) and in mice heterozygous for both Trp53^tm3.1Glo and Pml^tm1Ppp (504 days) (J:317504)

• strikingly, median survival is 414 days for male mice, i.e., >100 days shorter than in males heterozygous for Trp53^tm3.1Glo alone (515 days) and in males heterozygous for both Trp53^tm3.1Glo and Pml^tm1Ppp (539 days) (J:317504)

• average survival of male mice with soft tissue sarcomas (44%) is 380 days, i.e., even shorter than in males heterozygous for both Trp53^tm3.1Glo and Pml^tm1Ppp (443 days) which develop soft tissue sarcomas with a similar frequency (42%) (J:317504)

• however, median survival for female mice is 485 days, i.e., not significantly different from that in males heterozygous for Trp53^tm3.1Glo alone (515 days) (J:317504)

neoplasm

increased lymphoma incidence ( J:317504 )

• 36% of mice develop lymphomas (when expressed as a % of tumor type); 18% of mice develop two tumor types, lymphomas and sarcomas

• 44% of mice exhibit lymphomas when tumor incidence is evaluated per mouse and expressed as a % disease/total number of mice

• when tumors are segregated by gender, 44% of males and 44% of females exhibit lymphomas (expressed as a % disease/total number of mice)

increased T cell derived lymphoma incidence ( J:317504 )

• ~40% of lymphoid tumors are T-cell lymphomas

increased B cell derived lymphoma incidence ( J:317504 )

• immunophenotyping of lymphocytes from terminally resected tumors showed that ~60% of lymphoid tumors are B-cell lymphomas

increased carcinoma incidence ( J:317504 , J:317504 )

	• 5% of mice develop carcinomas (when expressed as a % of tumor type) (J:317504) • 6% of mice exhibit carcinomas (when expressed as a % disease/total number of mice) (J:317504)
	• when tumors are segregated by gender, 0% of males and 11% of females exhibit carcinomas (expressed as a % disease/total number of mice) (J:317504)

increased sarcoma incidence ( J:317504 )

• 59% of mice develop sarcomas (when expressed as a % of tumor type); 18% of mice develop two tumor types, lymphomas and sarcomas

• 72% of mice exhibit sarcomas (when expressed as a % disease/total number of mice)

• when tumors are segregated by gender, 44% of males and 11% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice), indicating that males lacking PML succumb to aggressive soft tissue sarcomas more frequently than females

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 33% of males and 56% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

• although osteosarcomas are proportionately more abundant in female mice, survival latency is not significantly altered

immune system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

liver/biliary system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:317504 )

• ~40% of lymphoid tumors are T-cell lymphomas

skeleton

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 33% of males and 56% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

• although osteosarcomas are proportionately more abundant in female mice, survival latency is not significantly altered

hematopoietic system

hematopoietic system phenotype ( J:317504 )

N	• zero of 18 mice (0%) exhibit extramedullary hematopoiesis (EMH) • when segregated by gender, neither male nor female mice exhibit EMH

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

growth/size/body

growth/size/body region phenotype ( J:317504 )

N	• average body weight is not significantly different from that in C57BL/6 wild-type controls

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

Allelic Composition	Pml^tm1Ppp/Pml⁺ Trp53^tm3.1Glo/Trp53⁺
Genetic Background	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:317504 )

• median survival for the combined population of both males and females is 504 days, i.e., similar to that of mice heterozygous for Trp53^tm3.1Glo alone (499 days)

• median survival is 539 days for male mice and 488 days for female mice, indicating that loss of a single Pml allele does not reduce the mean survival of either male or female Trp53^tm3.1Glo heterozygotes

decreased tumor-free survival time ( J:317504 )

• average survival of male mice that present with soft tissue sarcomas (42%) is 443 days

neoplasm

increased lymphoma incidence ( J:317504 )

• 43% of mice develop lymphomas (when expressed as a % of tumor type); 14% of mice develop two tumor types, lymphomas and sarcomas

• 38% of mice exhibit lymphomas when tumor incidence is evaluated per mouse, including those that succumb to EMH, and expressed as a % disease/total number of mice

• when tumors are segregated by gender, 33% of males and 42% of females exhibit lymphomas (expressed as a % disease/total number of mice)

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

increased B cell derived lymphoma incidence ( J:317504 )

• immunophenotyping of lymphocytes from terminally resected tumors showed that ~80% of lymphoid tumors are B-cell lymphomas

increased carcinoma incidence ( J:317504 , J:317504 )

	• 5% of mice develop carcinomas (when expressed as a % of tumor type) (J:317504) • 4% of mice exhibit carcinomas (when expressed as a % disease/total number of mice) (J:317504)
	• when tumors are segregated by gender, 0% of males and 8% of females exhibit carcinomas (expressed as a % disease/total number of mice) (J:317504)

increased sarcoma incidence ( J:317504 )

• 52% of mice develop sarcomas (when expressed as a % of tumor type); 14% of mice develop two tumor types, lymphomas and sarcomas

• 46% of mice exhibit sarcomas (when expressed as a % disease/total number of mice)

• when tumors are segregated by gender, 42% of males and 17% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice)

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 8% of males and 25% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

hematopoietic system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

extramedullary hematopoiesis ( J:317504 )

• 33% mice exhibit extramedullary hematopoiesis (EMH)

• when segregated by gender, 33% of males and 33% of females exhibit EMH

immune system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

liver/biliary system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

growth/size/body

decreased body weight ( J:317504 )

• average body weight is significantly lower than that in C57BL/6 wild-type controls

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53^tm3.1Glo alone

skeleton

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 8% of males and 25% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

Allelic Composition	Pml^tm1Ppp/Pml^tm1Ppp Trp53^tm3.1Glo/Trp53^tm3.1Glo
Genetic Background	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:317504 )

• mean survival of male mice is 156.5 days i.e., not significantly different from that in males homozygous for Trp53^tm3.1Glo alone (164.5 days)

prenatal lethality, incomplete penetrance ( J:317504 )

• only 9% of females are born, indicating a severe reduction in female survival

Allelic Composition	Mdm2^tm3.1Glo/Mdm2^tm3.1Glo Trp53^tm3.1Glo/Trp53⁺
Genetic Background	B6.129S-Mdm2^tm3.1Glo Trp53^tm3.1Glo

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mdm2^tm3.1Glo mutation (0 available); any Mdm2 mutation (54 available)
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:164201 )

• overall survival is reduced relative to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53^tm3.1Glo

cellular

decreased cellular sensitivity to ionizing radiation ( J:164201 )

• in the thymus following a low dose of IR radiation compared to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53^tm3.1Glo

neoplasm

increased tumor incidence ( J:164201 )

• accelerated tumor onset relative to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53^tm3.1Glo

• the tumor spectrum is also altered relative to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53^tm3.1Glo

• mice develop multiple primary tumors

increased liver adenoma incidence ( J:164201 )

• in 1 mouse

increased lung adenoma incidence ( J:164201 )

• in 1 mouse

increased lipoma incidence ( J:164201 )

increased lymphoma incidence ( J:164201 )

increased histiocytic sarcoma incidence ( J:164201 )

increased carcinoma incidence ( J:164201 )

• salivary carcinoma in 1 mouse

• undefined carcinomas are also reported

increased adenocarcinoma incidence ( J:164201 )

increased mammary adenocarcinoma incidence ( J:164201 )

increased liver adenocarcinoma incidence ( J:164201 )

• in 1 mouse

increased squamous cell carcinoma incidence ( J:164201 )

increased sarcoma incidence ( J:164201 )

• soft tissue sarcoma

• chondrosarcoma in 1 mouse

increased leiomyosarcoma incidence ( J:164201 )

• in 1 mouse

increased fibrosarcoma incidence ( J:164201 )

increased hemangiosarcoma incidence ( J:164201 )

• ovarian

increased osteosarcoma incidence ( J:164201 )

increased papilloma incidence ( J:164201 )

• squamous cell papilloma in 1 mouse

muscle

increased leiomyosarcoma incidence ( J:164201 )

• in 1 mouse

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:164201 )

integument

increased mammary adenocarcinoma incidence ( J:164201 )

skeleton

increased osteosarcoma incidence ( J:164201 )

liver/biliary system

increased liver adenocarcinoma incidence ( J:164201 )

• in 1 mouse

increased liver adenoma incidence ( J:164201 )

• in 1 mouse

respiratory system

increased lung adenoma incidence ( J:164201 )

• in 1 mouse

Allelic Composition	Mdm2^tm4.1Glo/Mdm2^tm4.1Glo Trp53^tm3.1Glo/Trp53⁺
Genetic Background	B6.129S-Mdm2^tm4.1Glo Trp53^tm3.1Glo

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mdm2^tm4.1Glo mutation (0 available); any Mdm2 mutation (54 available)
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased lymphoma incidence ( J:164201 )

• in 1 mouse

increased histiocytic sarcoma incidence ( J:164201 )

increased carcinoma incidence ( J:164201 )

• an undefined carcinoma is reported in 1 mouse

increased adenocarcinoma incidence ( J:164201 )

• undefined adenocarcinomas are reported

increased liver adenocarcinoma incidence ( J:164201 )

increased squamous cell carcinoma incidence ( J:164201 )

• in 1 mouse

increased sarcoma incidence ( J:164201 )

• soft tissue sarcoma

increased fibrosarcoma incidence ( J:164201 )

increased osteosarcoma incidence ( J:164201 )

skeleton

increased osteosarcoma incidence ( J:164201 )

liver/biliary system

increased liver adenocarcinoma incidence ( J:164201 )

Allelic Composition	Mdm4^tm3.1Glo/Mdm4^tm3.1Glo Trp53^tm3.1Glo/Trp53^tm3.1Glo
Genetic Background	involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mdm4^tm3.1Glo mutation (0 available); any Mdm4 mutation (191 available)
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

mortality/aging ( J:174368 )

N	• unlike mice homozygous the Mdm4 allele alone, double mutant mice are viable

Allelic Composition	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm3.1Glo/Trp53^tm4Glo
Genetic Background	involves: 129S7/SvEvBrd * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mdm2^tm1Glo mutation (0 available); any Mdm2 mutation (54 available)
Trp53^tm3.1Glo mutation (0 available); any Trp53 mutation (232 available)
Trp53^tm4Glo mutation (0 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

mortality/aging ( J:171821 )

N	• lethality observed in Mdm2^tm1Glo homozygotes is completely rescued with mice surviving beyond 5 weeks

Allelic Composition	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm3.1Glo/Trp53⁺
Genetic Background	involves: 129S7/SvEvBrd * C57BL/6

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

prenatal lethality, complete penetrance ( J:95318 )

• no newborn mice are recovered

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/16/2024 MGI 6.23